V CompBrief BY VELARION

Chief Business Officer · ARS Pharmaceuticals, Inc. (SPRY)

Justin Chakma

FY2025 is the first fiscal year CompBrief holds for Justin Chakma as a named executive officer of ARS Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$2,888,109

3rd of 3 named executive officers at ARS Pharmaceuticals by FY2025 total.

3 named officers on file for ARS Pharmaceuticals, FY2025

See an example →

What this number hides

The filing gives the total. ARS Pharmaceuticals’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how ARS Pharmaceuticals’s whole pay program stands against its peers

  • ARS Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

Free

Get Justin Chakma’s full pay file as a PDF — free

More than this page: up to 10 years of Justin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Justin Chakma and every company like it: Velarion Intel, free for 3 days, no card →

Justin Chakma compensation by year

ARS Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as ARS Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$497,000
Option awards$2,205,409
Non-equity incentive$164,000
All other$21,700
Total$2,888,109

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191433, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0001193125-26-191433. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option44,688—$8.42
Option182,292—$5.58
Option211,286—$10.71

Per the Outstanding Equity Awards at Fiscal Year-End table in ARS Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

ARS Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Richard LowenthalPresident and Chief Executive Officer$9,656,400
Sarina TanimotoChief Medical Officer$5,290,471
Justin Chakma · this pageChief Business Officer$2,888,109

Justin Chakma's compensation dossier, ARS Pharmaceuticals

You have read Justin Chakma's totals and holdings. The dossier adds each equity grant ARS Pharmaceuticals disclosed for Justin Chakma and ARS Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full ARS Pharmaceuticals compensation record

free company brief
ARS Pharmaceuticals, Inc. (SPRY) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARS Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ARS Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order SPRY

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Justin Chakma's compensation dossier